Objective: To identify dietary factors in commercially available canned foods associated with the development of calcium oxalate (CaOx) uroliths in dogs.

Animals: 117 dogs with CaOx uroliths and 174 dogs without urinary tract disease.

Procedure: Case dogs were those that developed CaOx uroliths submitted to the Minnesota Urolith Center for quantitative analysis between 1990 and 1992 while fed a commercially available canned diet. Control dogs were those without urinary tract disease evaluated at the same veterinary hospital just prior to or immediately after each case dog. A content-validated multiple-choice questionnaire was mailed to each owner of case and control dogs with the permission of the primary care veterinarian. Univariate and multivariate logistic regressions for each dietary component were performed to test the hypothesis that a given factor was associated with CaOx urolith formation.

Results: Canned foods with the highest amount of protein, fat, calcium, phosphorus, magnesium, sodium, potassium, chloride, or moisture were associated with a decreased risk of CaOx urolith formation, compared with diets with the lowest amounts. In contrast, canned diets with the highest amount of carbohydrate were associated with an increased risk of CaOx urolith formation.

Conclusions And Clinical Relevance: Feeding canned diets formulated to contain high amounts of protein, fat, calcium, phosphorus, magnesium, sodium, potassium, chloride, and moisture and a low amount of carbohydrate may minimize the risk of CaOx urolith formation in dogs.

Download full-text PDF

Source
http://dx.doi.org/10.2460/ajvr.2002.63.163DOI Listing

Publication Analysis

Top Keywords

caox urolith
16
caox uroliths
12
risk caox
12
dietary factors
8
calcium oxalate
8
commercially canned
8
canned foods
8
dogs urinary
8
urinary tract
8
control dogs
8

Similar Publications

Article Synopsis
  • A study investigated the effectiveness of empagliflozin, a sodium-glucose cotransporter 2 inhibitor, in preventing kidney stones in nondiabetic adults with a history of calcium or uric acid stones.
  • The trial involved 53 participants who were given either empagliflozin or a placebo in a crossover design, focusing on changes in urine supersaturation ratios relevant to stone recurrence.
  • Results showed significant reductions in urine supersaturation ratios for calcium phosphate in calcium stone formers and uric acid in uric acid stone formers, indicating that empagliflozin may help prevent certain types of kidney stones without serious side effects.
View Article and Find Full Text PDF

Sulfated Polysaccharides Inhibit CaOx Stone Formation by Inhibiting Calcium Oxalate Crystallization, Cellular Inflammation, and Crystal Adhesion.

J Agric Food Chem

January 2025

Institute of Biomineralization and Lithiasis Research, College of Chemistry and Materials Science, Jinan University, Guangzhou 510632, China.

Hyperoxaluria can easily induce calcium oxalate (CaOx) crystals and cause cell damage, thereby increasing the risk of kidney stone formation. In this study, three sulfated polysaccharides (PSPs) were obtained by the sulfur trioxide-pyridine method. The antioxidant activity of PSPs and the inhibitory effects of PSPs on CaOx crystallization, cellular oxidative damage, and cellular inflammation were explored in vitro, and PSPs were used to treat hyperoxaluria-induced crystallization model mice in order to validate the stone-preventive effect of PSPs in vivo.

View Article and Find Full Text PDF

The early stages of kidney crystal formation involve inflammation and hypoxia-induced cell injury; however, the role of the hypoxic response in kidney crystal formation remains unclear. This study investigated the effects of a prolyl hydroxylase domain inhibitor (roxadustat) on renal calcium oxalate (CaOx) crystal formation through in vitro and in vivo approaches. In the in vitro experiment, murine renal tubular cells (RTCs) were exposed to varying roxadustat concentrations and CaOx crystals.

View Article and Find Full Text PDF

In calcium stone formers, most stones grow attached to Randall's plaque, which can be identified by measuring the computed tomography (CT) attenuation value of renal papilla. We hypothesized that the CT attenuation value of renal papilla can predict the severity (recurrent or multiple stone former) and recurrence of the stone disease. We retrospectively reviewed the charts of 180 calcium oxalate stone formers who underwent non-contrast CT and 24-hour urine chemistry in our hospital between September 2012 and November 2021.

View Article and Find Full Text PDF

The SIRT6 allosteric activator MDL-800 suppresses calcium oxalate nephrocalcinosis by alleviating inflammatory and renal damage.

Int Immunopharmacol

January 2025

Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Institute of Urology, Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, China. Electronic address:

Article Synopsis
  • Kidney stones are primarily made of calcium oxalate and can cause inflammation and damage in kidney cells, leading to a condition known as CaOx nephrocalcinosis.
  • The study tested a new drug, MDL-800, which acts as an allosteric agonist for Sirtuin 6 (SIRT6), showing it can reduce kidney cell damage and inflammation caused by calcium oxalate crystals in both cell cultures and animal models.
  • MDL-800 works by decreasing levels of inflammatory proteins and enhancing SIRT6's function, offering a potential new treatment approach for kidney damage linked to calcium oxalate stones.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!